Journal of Thrombosis and Thrombolysis

, Volume 42, Issue 4, pp 573–578 | Cite as

Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation

Article

Abstract

Atrial fibrillation (AF) is a major risk factor for stroke in the elderly population. The use of anticoagulation in patients with AF greatly reduces the risk for stroke, but results in an increased risk of bleeding. Over the past several years, direct oral anticoagulants (DOACs, dabigatran, rivaroxaban, and apixaban) have been used in place of warfarin for stroke prevention in AF. We conducted a retrospective cohort study to assess the safety of DOACs in very elderly patients (75+) managed in a health care system encompassing both community and academic settings. We found that 36 % of patients had moderate to severe renal failure (estimated glomerular filtration rate <59 ml/min/1.73 m2) at the time of DOAC initiation. 142 patients were followed for a mean of 2.56 years, and five experienced a major bleeding episode while on anticoagulation, for a rate of 1.37 per 100 person years. All major bleeding episodes were associated with a decline in GFR compared to baseline. There were 12 non-major bleeding episodes reported. HAS-BLED scores were similar for those patients who experienced bleeding complications compared to those who did not. 21 % of patients were prescribed an inappropriately low dose of DOAC based on approved recommendations. DOACs appear to be a safe form of anticoagulation in very elderly patients with AF. However, the decline in GFR among patients with major bleeding highlights the importance of routine renal function monitoring.

Keywords

Direct oral anticoagulants Rivaroxaban Dabigatran Apixaban Elderly Bleeding Atrial fibrillation 

Notes

Acknowledgments

Funding for Fatima Khan, M.B.B.S., was supported by National Institutes of Health T32 Hematology research training Grant (5T32HL00706). Research reported in this publication was supported in part by Grant number UL1TR000114 from the National Center for Advancing Translational Sciences of the National Institutes of Health. The clinical data was provided by the University of Minnesota’s Informatics Consulting Service.

Compliance with ethical standards

Financial disclosures and conflicts of interest

All authors declare no conflicting financial interest.

Ethical approval

This study was conducted with the approval of the University of Minnesota Institutional Review Board.

References

  1. 1.
    Go AS et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285(18):2370–2375CrossRefPubMedGoogle Scholar
  2. 2.
    Reiffel JA (2014) Atrial fibrillation and stroke: epidemiology. Am J Med 127(4):e15–e16Google Scholar
  3. 3.
    Suarez Fernandez C et al (2015) Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovasc Disord 15:143CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Connolly SJ et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefPubMedGoogle Scholar
  5. 5.
    Patel MR et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891CrossRefPubMedGoogle Scholar
  6. 6.
    Granger CB et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRefPubMedGoogle Scholar
  7. 7.
    Giugliano RP et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104CrossRefPubMedGoogle Scholar
  8. 8.
    Halperin JL et al (2014) Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 130(2):138–146CrossRefPubMedGoogle Scholar
  9. 9.
    Eikelboom JW et al (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21):2363–2372CrossRefPubMedGoogle Scholar
  10. 10.
    Halvorsen S et al (2014) Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 35(28):1864–1872CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lip GY et al (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57(2):173–180CrossRefPubMedGoogle Scholar
  12. 12.
    Schulman S et al (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694CrossRefPubMedGoogle Scholar
  13. 13.
    Mant J et al (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet 370(9586):493–503CrossRefPubMedGoogle Scholar
  14. 14.
    Scowcroft AC, Lee S, Mant J (2013) Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the general practice research database (GPRD) 2000-2009. Heart 99(2):127–132CrossRefPubMedGoogle Scholar
  15. 15.
    Rosenman MB et al (2012) Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin 28(9):1407–1414CrossRefPubMedGoogle Scholar
  16. 16.
    Sharma M et al (2015) Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132(3):194–204CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ng KH et al (2016) Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing 45(1):77–83CrossRefPubMedGoogle Scholar
  18. 18.
    Camm AJ et al (2016) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37(14):1145–1153CrossRefPubMedGoogle Scholar
  19. 19.
    Tamayo S et al (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38(2):63–68CrossRefPubMedGoogle Scholar
  20. 20.
    Abraham NS et al (2015) Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 350:h1857CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pasca S et al (2015) Direct oral anticoagulants for very elderly people with atrial fibrillation: efficacy and safe enough? Clin Appl Thromb Hemost. doi: 10.1177/1076029615619485 Google Scholar
  22. 22.
    Gladstone DJ et al (2015) How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 163(5):382–385CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Division of Hematology, Oncology and TransplantationUniversity of Minnesota Medical SchoolMinneapolisUSA
  2. 2.Department of MedicineUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations